Who Paid My Doc
Avina Singh
Hematology & Oncology Burnsville, MN Medical Doctor
NPI 1821201666 CMS profile 785452
675 E Nicollet Blvd Ste 100, Burnsville, MN 55337
General payments
$168
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$379,153
Through program year 2022, Avina Singh of Burnsville, MN is reported in the CMS Open Payments database as having received $168 across 4 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $379,153 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 15th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
3 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $142 | 2 | |
| 2021 | General | $12 | 1 | |
| 2019 | General | $14 | 1 |
Beside peers
- Avina Singh
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to Avina Singh were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | Avina Singh | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $14 | $529 | $121–$2,516 | $163 |
| 2020 | $0 | $339 | $82–$2,213 | $114 |
| 2021 | $12 | $263 | $49–$1,965 | $132 |
| 2022 | $142 | $416 | $103–$2,395 | $149 |
| 2023 | $0 | $542 | $125–$2,646 | $160 |
| 2024 | $0 | $692 | $141–$3,008 | $164 |
| 2025 | $0 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 38 drugsPart D claims
1,503
Drug cost
$3,811,673
Branded share of claims
27.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Revlimid Lenalidomide | Brand | 48 | $884,767 | |
| Calquence Acalabrutinib Maleate | Brand | 48 | $701,567 | |
| Ibrance Palbociclib | Brand | 36 | $557,241 | |
| Kisqali Ribociclib Succinate | Brand | 22 | $328,821 | |
| Jakafi Ruxolitinib Phosphate | Brand | 15 | $248,199 | |
| Alecensa Alectinib Hcl | Brand | 13 | $217,016 | |
| Verzenio Abemaciclib | Brand | 14 | $206,454 | |
| Imbruvica Ibrutinib | Brand | 13 | $203,598 | |
| Ninlaro Ixazomib Citrate | Brand | 13 | $160,710 | |
| Venclexta Venetoclax | Brand | 23 | $135,150 |
The 10 drugs with the highest cost, of 38 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 167 billing codesPaid by Medicare
$3,092,443
Medicare patients
430
Services billed
163,618
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 64% | |
| Cancer | 58% | |
| Arthritis | 36% | |
| Chronic kidney disease | 27% | |
| Depression | 24% | |
| Diabetes | 23% | |
| Ischemic heart disease | 21% | |
| Atrial fibrillation | 20% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, pembrolizumab, 1 mg J9271 | Office | 18 | 13,000 | $580,906 |
| Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg J1568 | Office | 14 | 1,840 | $68,241 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg Q5119 | Office | 11 | 1,580 | $25,295 |
| Injection, aprepitant, 1 mg J0185 | Office | 36 | 17,680 | $23,827 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) J0881 | Office | 11 | 8,150 | $18,770 |
| Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg Q5122 | Office | 12 | 324 | $18,264 |
| Leuprolide acetate (for depot suspension), 7.5 mg J9217 | Office | 13 | 59 | $8,295 |
| Injection, leucovorin calcium, per 50 mg J0640 | Office | 11 | 720 | $2,592 |
| Injection, fluorouracil, 500 mg J9190 | Office | 12 | 482 | $1,095 |
| Injection, palonosetron hcl, 25 mcg J2469 | Office | 39 | 1,500 | $1,073 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
4 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Hematology & Oncology in Minnesota
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Minnesota
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.